Viela Bio, Inc. Common Stock
VIE
VIE was delisted on the 12th of March, 2021.
65 hedge funds and large institutions have $1.09B invested in Viela Bio, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 30 increasing their positions, 8 reducing their positions, and 6 closing their positions.
300% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 6
275% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 8
48% more capital invested
Capital invested by funds: $732M → $1.09B (+$354M)
38% more funds holding
Funds holding: 47 → 65 (+18)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$148M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$82.4M |
| 3 |
BlackRock
New York
|
+$41M |
| 4 |
State Street
Boston,
Massachusetts
|
+$24.4M |
| 5 |
Goldman Sachs
New York
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$80.4M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$11.3M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$9.1M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$1.07M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$363K |
VIE Hedge Fund Activity: Q2 2020 in Review
65 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Viela Bio, Inc. Common Stock (VIE) for Q2 2020, worth a combined $1.09B — up 48% from $732M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new VIE positions and 6 closed out — a net gain of 18 holders — while 30 added to existing stakes and 8 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $148M. The largest seller was HHLR Advisors, cutting an estimated $80.4M.
- 65 institutional investors held Viela Bio, Inc. Common Stock (VIE) as of Q2 2020, up from 47 in Q1 2020.
- Funds reported $1.09B of Viela Bio, Inc. Common Stock stock for Q2 2020, up 48% quarter-over-quarter.
- 24 funds opened new Viela Bio, Inc. Common Stock positions in Q2 2020 and 6 closed out, a net change of +18 holders.
- The largest Viela Bio, Inc. Common Stock buyer in Q2 2020 was Fidelity Investments, an estimated $148M added.
- The largest Viela Bio, Inc. Common Stock seller in Q2 2020 was HHLR Advisors, an estimated $80.4M sold.
Based on aggregated 13F filings for Q2 2020.